Genmab A/S GMAB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 06/24/22 EDT
32.31UNCH (UNCH)
Volume
451
Close
32.31quote price arrow up+1.22 (+3.92%)
Volume
547,748
52 week range
26.19 - 49.07
Loading...
  • Open32.19
  • Day High32.34
  • Day Low31.47
  • Prev Close31.09
  • 52 Week High49.07
  • 52 Week High Date09/02/21
  • 52 Week Low26.19
  • 52 Week Low Date06/16/22

Key Stats

  • Market Cap21.245B
  • Shares Out657.53M
  • 10 Day Average Volume0.63M
  • Dividend-
  • Dividend Yield-
  • Beta0.62
  • YTD % Change-18.33

KEY STATS

  • Open32.19
  • Day High32.34
  • Day Low31.47
  • Prev Close31.09
  • 52 Week High49.07
  • 52 Week High Date09/02/21
  • 52 Week Low26.19
  • 52 Week Low Date06/16/22
  • Market Cap21.245B
  • Shares Out657.53M
  • 10 Day Average Volume0.63M
  • Dividend-
  • Dividend Yield-
  • Beta0.62
  • YTD % Change-18.33

RATIOS/PROFITABILITY

  • EPS (TTM)0.54
  • P/E (TTM)60.35
  • Fwd P/E (NTM)5.81
  • EBITDA (TTM)424.442M
  • ROE (TTM)11.10%
  • Revenue (TTM)1.276B
  • Gross Margin (TTM)-
  • Net Margin (TTM)26.35%
  • Debt To Equity (MRQ)1.83%

EVENTS

  • Earnings Date08/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Genmab A/S

There is no recent news for this security.

Profile

MORE
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment...
Deirdre Connelly
Independent Chairman of the Board
Jan Van De Winkel Ph.D.
President, Chief Executive Officer
Anthony Mancini
Chief Operating Officer, Executive Vice President
Anthony Pagano
Chief Financial Officer, Executive Vice President
Judith Klimovsky M.D.
Executive Vice President, Chief Development Officer
Address
Kalvebod Brygge 43
Koebenhavn V
1560
Denmark

Top Peers

SYMBOLLASTCHG%CHG
ALNY
Alnylam Pharmaceuticals Inc
147.50+1.20+0.82%
NVZMY
Novozymes A/S
59.49+3.26+5.80%
INCY
Incyte Corp
78.19+3.41+4.56%
BHVN
Biohaven Pharmaceutical Holding Company Ltd
143.79-0.41-0.28%
NBIX
Neurocrine Biosciences Inc
98.24+0.84+0.86%